[
    [
        {
            "time": "2018-01-29",
            "original_text": "Health Care Sector Update for 01/29/2018: ABLX,SNY,NVO,BTX,ARDM",
            "features": {
                "keywords": [
                    "ABLX",
                    "SNY",
                    "NVO",
                    "BTX",
                    "ARDM"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 01/29/2018: ABLX,SNY,NVO,BTX,ARDM",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars",
            "features": {
                "keywords": [
                    "AKCA",
                    "MNLO",
                    "OBSV",
                    "ARGX"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done",
            "features": {
                "keywords": [
                    "Sanofi",
                    "billion-dollar deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo Nordisk",
                    "Ablynx"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo",
                    "Ablynx",
                    "biotech",
                    "M&A"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Could Sanofi's Ablynx Deal Spur A Biopharma Buying Spree?",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Ablynx",
                    "Biopharma"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Could Sanofi's Ablynx Deal Spur A Biopharma Buying Spree?",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "France's Sanofi buys biotech company Ablynx for $4.8 billion",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Ablynx",
                    "biotech"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "France's Sanofi buys biotech company Ablynx for $4.8 billion",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo",
                    "Ablynx",
                    "biotech",
                    "M&A"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Q4 Results",
                    "Earnings Call"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi Will Buy Ablynx For $4.8 Billion On Heels Of $11.6 Billion Bioverativ Deal",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Ablynx",
                    "Bioverativ"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi Will Buy Ablynx For $4.8 Billion On Heels Of $11.6 Billion Bioverativ Deal",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Indexes Edge Lower: Dr. Pepper Surges, Goldman Leads Dow",
            "features": {
                "keywords": [
                    "Indexes",
                    "Dr. Pepper",
                    "Goldman",
                    "Dow"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Indexes Edge Lower: Dr. Pepper Surges, Goldman Leads Dow",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi's $16 Billion Splurge Leaves Novo Behind on Blood Deals",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo",
                    "Blood Deals"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi's $16 Billion Splurge Leaves Novo Behind on Blood Deals",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "INTERVIEW: Novo Nordisk remains on hunt for biopharma deals",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "biopharma deals"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "INTERVIEW: Novo Nordisk remains on hunt for biopharma deals",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Novo Nordisk remains on hunt for biopharma deals",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "biopharma deals"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Novo Nordisk remains on hunt for biopharma deals",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo",
                    "Ablynx",
                    "Cash Bid"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize",
            "features": {
                "keywords": [
                    "Ablynx",
                    "Camel Blood",
                    "Prize"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 5
            }
        }
    ]
]